Literature DB >> 657047

Adverse biochemical and clinical consequences of furosemide administration.

M Spino, E M Sellers, H L Kaplan, C Stapleton, S M MacLeod.   

Abstract

Nurse monitors collected clinical and laboratory data from 204 hospitalized patients receiving furosemide (122 men and 82 women; mean age 69.6 years). Biochemical abnormalities and clinical problems definitely or probably induced by any drug occurred in 70.6% and 49.0% respectively of the patients, and were attributed to furosemide in 81.3% and 13.0% respectively of these patients. The most important clinical events were dehydration and hypotension. Furosemide-induced hypochloremia, hypokalemia and hyponatremia occurred in 35.8%, 25.0% and 24.5% of the patients respectively. Most of the biochemical changes were slight, and only 3.9% of the patients had a furosemide-induced decrease in the serum potassium concentration to less than 3.0 mmol/L. Surprisingly, 24.5% of the patients also manifested drug-induced hyperkalemia. Administration potassium supplements or spironolactone, or both, concurrently with furosemide was responsible in most cases for the development of hyperkalemia. The occurrence of drug-induced adverse effects after 2 weeks of hospitalization was significantly associated (P less than 0.05) with subsequent prolongation of hospitalization. The high frequency of drug-induced events warrants careful monitoring of all patients receiving furosemide in spite of the low frequency of serious toxic effects produced by the drug.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 657047      PMCID: PMC1818104     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  10 in total

1.  Adverse drug reactions. A critical review.

Authors:  F E Karch; L Lasagna
Journal:  JAMA       Date:  1975-12-22       Impact factor: 56.272

2.  Short-term intense surveillance of adverse drug reactions.

Authors:  T K Gray; L L Adams; H J Fallon
Journal:  J Clin Pharmacol New Drugs       Date:  1973 Feb-Mar

Review 3.  Toxicity of ethacrynic acid and furosemide.

Authors:  L B Cooperman; I L Rubin
Journal:  Am Heart J       Date:  1973-06       Impact factor: 4.749

Review 4.  Ethacrynic acid and furosemide. Diuretic and hemodynamic effects and clinical uses.

Authors:  K E Kim; G Onesti; J H Moyer; C Swartz
Journal:  Am J Cardiol       Date:  1971-04       Impact factor: 2.778

5.  Furosemide. A clinical evaluation of its diuretic action.

Authors:  W B Stason; P J Cannon; H O Heinemann; J H Laragh
Journal:  Circulation       Date:  1966-11       Impact factor: 29.690

6.  Intensive hospital monitoring of adverse reactions to drugs.

Authors:  N Hurwitz; O L Wade
Journal:  Br Med J       Date:  1969-03-01

7.  Diuretic and clinical effects of low-dose furosemide in congestive heart failure patients.

Authors:  R N Mahabir; R Bacchus
Journal:  J Clin Pharmacol       Date:  1976-10       Impact factor: 3.126

8.  Clinical toxicity of furosemide in hospitalized patients. A report from the Boston Collaborative Drug Surveillance Program.

Authors:  D J Greenblatt; D W Duhme; M D Allen; J Koch-Weser
Journal:  Am Heart J       Date:  1977-07       Impact factor: 4.749

9.  Adverse reactions during hospitalization.

Authors:  R I Ogilvie; J Ruedy
Journal:  Can Med Assoc J       Date:  1967-12-09       Impact factor: 8.262

10.  Studies on the epidemiology of adverse drug reactions. V. Clinical factors influencing susceptibility.

Authors:  J W Smith; L G Seidl; L E Cluff
Journal:  Ann Intern Med       Date:  1966-10       Impact factor: 25.391

  10 in total
  9 in total

1.  EIDOS: a mechanistic classification of adverse drug effects.

Authors:  Robin E Ferner; Jeffrey K Aronson
Journal:  Drug Saf       Date:  2010-01-01       Impact factor: 5.606

2.  Adverse Drug Reactions: Review of the Canadian literature.

Authors:  J Lexchin
Journal:  Can Fam Physician       Date:  1991-01       Impact factor: 3.275

Review 3.  Diuretics. Clinical pharmacology and therapeutic use (Part II).

Authors:  A Lant
Journal:  Drugs       Date:  1985-02       Impact factor: 9.546

4.  The clinical features of covert diuretic use.

Authors:  D I Spratt; A Pont
Journal:  West J Med       Date:  1982-10

5.  Diuretic-related hypokalaemia: the role of diuretics, potassium supplements, glucocorticoids and beta 2-adrenoceptor agonists. Results from the comprehensive hospital drug monitoring programme, berne (CHDM).

Authors:  P Widmer; R Maibach; U P Künzi; R Capaul; U Mueller; R Galeazzi; R Hoigné
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

6.  Postdischarge adverse drug reactions in primary care originating from hospital care in France: a nationwide prospective study.

Authors:  L Letrilliart; T Hanslik; M Biour; J P Fagot; M Guiguet; A Flahault
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 7.  Interventions for the management of transient tachypnoea of the newborn - an overview of systematic reviews.

Authors:  Matteo Bruschettini; Karl-Omar Hassan; Olga Romantsik; Rita Banzi; Maria Grazia Calevo; Luca Moresco
Journal:  Cochrane Database Syst Rev       Date:  2022-02-24

8.  Hypokalemia during the treatment of arterial hypertension with diuretics.

Authors:  G Lemieux; M Beauchemin; P Vinay; A Gougoux
Journal:  Can Med Assoc J       Date:  1980-04-19       Impact factor: 8.262

9.  Differences between acute and long-term metabolic and endocrine effects of oral beta-adrenoceptor agonist therapy with pirbuterol for cardiac failure.

Authors:  R Canepa-Anson; J R Dawson; P Kuan; P A Poole-Wilson; G C Sutton; B Cockrill; S R Reuben
Journal:  Br J Clin Pharmacol       Date:  1987-02       Impact factor: 4.335

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.